- In April 2024, Pfizer Inc. announced positive overall survival results from its Phase III ECHELON-3 trial, evaluating ADCETRIS plus lenalidomide and rituximab versus lenalidomide and rituximab plus placebo in adult patients with relapsed/refractory diffuse large B-cell lymphoma. The study demonstrated a significant improvement in patient outcomes, positioning the combination as a potential advancement in oncology supportive care
- In March 2024, GlaxoSmithKline (GSK) launched a new over-the-counter (OTC) formulation of Dramamine XR, an extended-release antihistamine aimed at preventing motion sickness and associated vomiting. This product caters to travelers seeking long-lasting relief, reflecting GSK's commitment to expanding its consumer healthcare portfolio
- In February 2024, Johnson & Johnson's Janssen Pharmaceuticals received FDA approval for IMAAVY™ (nipocalimab), a novel FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG). This approval underscores the company's commitment to developing treatments that address unmet medical needs
- In January 2024, Novartis AG entered into a strategic collaboration with Voyager Therapeutics to license novel capsids for use in gene therapy programs. This partnership aims to enhance the delivery of gene therapies, potentially benefiting various therapeutic areas, including those addressing vomiting and nausea
- In December 2023, Sanofi S.A. presented new data at the American Society of Hematology (ASH) 2023, highlighting its commitment to innovation in rare blood diseases and cancers. While not directly related to vomiting treatments, advancements in oncology can have implications for managing chemotherapy-induced nausea and vomiting
